DAC SRL has a total of 64 patent applications. Its first patent ever was published in 2004. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are AISSAOUI HAMED, PREDIX PHARMACEUTICALS HOLDING and FAES FABRICA ESPANOLA DE PRODU.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 11 | |
#2 | WIPO (World Intellectual Property Organization) | 8 | |
#3 | Australia | 5 | |
#4 | Canada | 5 | |
#5 | China | 5 | |
#6 | United States | 5 | |
#7 | Hong Kong | 4 | |
#8 | Mexico | 4 | |
#9 | Israel | 3 | |
#10 | Italy | 3 | |
#11 | Republic of Korea | 3 | |
#12 | New Zealand | 3 | |
#13 | South Africa | 3 | |
#14 | Brazil | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Minucci Saverio | 48 |
#2 | Thaler Florian | 38 |
#3 | Varasi Mario | 29 |
#4 | Mercurio Ciro | 29 |
#5 | Colombo Andrea | 22 |
#6 | Mai Antonello | 22 |
#7 | Abate Agnese | 19 |
#8 | Gagliardi Stefania | 19 |
#9 | Carenzi Giacomo | 13 |
#10 | Ballarini Marco | 11 |
Publication | Filing date | Title |
---|---|---|
WO2013064919A1 | Quinazoline derivatives with hsp90 inhibitory activity | |
EP2311840A1 | Spirocyclic derivatives as histone deacetylase inhibitors | |
EP2133334A1 | Heterocyclic derivatives as HDAC inhibitors | |
WO2008142720A2 | Quinazolin-oxime derivatives as hsp90 inhibitors | |
EP2110377A1 | Spirocyclic derivatives as histone deacetylase inhibitors | |
EP2033956A1 | A new class of histone deacetylase inhibitors | |
WO2007113249A2 | N-hydroxy-3-(4-{3-phenyl-s-oxo-propenyl}-phenyl)-acrylamide derivatives and related compounds as histone deacetylase inhibitors for the treatment of cancer | |
NZ554640A | New histone deacetylases inhibitors |